Led · Equity · Sep 2025

Facephi secured financing of up to €1.5 million from its majority shareholder Nice & Green to cover the company’s operating needs. The financing was disclosed on BME Growth. €1 million was delivered at signing on September 2, and the remaining €500,000 is available for drawdown when required. The funds take the form of a loan that accrues variable interest equal to the one‑month Euribor plus 3.50%. The loan has a maximum maturity date of January 31, 2026 and carried a €1,000 formalization fee. The agreement specifies the debt is non‑convertible and must be repaid as financial indebtedness. FacePhi develops AI-based biometric technologies including face, fingerprint, pupil, and voice recognition for authentication. The company is listed on the Spanish and French stock exchanges and operates mainly in Europe and Latin America, with a substantial customer base among financial companies in Korea. FacePhi emphasizes passive anti-spoofing (authenticating identity with a single frontal facial image) and in 2022 received i-Beta Level 2 certification from NIST, placing it among nine passive i-Beta Level 2 companies worldwide. The firm’s passive anti-forgery approach is positioned as a next-generation method as the market shifts toward facial recognition to counter deepfakes. Under the strategic tie-up with Hancom, FacePhi’s multi-recognition biometric technology will be combined with Hancom’s AI, security, reporting, and healthcare tools to develop new services and expand distribution in APAC via white-labeling.

Led · Convertible Note · Nov 2023

Oryzon leverages epigenetics to develop small-molecule therapies, with a strong focus on personalized medicine in CNS disorders and oncology. Its advanced clinical portfolio centers on two LSD1 inhibitors: vafidemstat (CNS) and iadademstat (oncology), both in multiple Phase II trials. Vafidemstat is in Phase IIb studies including PORTICO (borderline personality disorder) and EVOLUTION (schizophrenia) and Oryzon is preparing additional trials (e.g., Kabuki Syndrome and other neurodevelopmental indications). Iadademstat has been evaluated across several trials (including FRIDA, ALICE and CLEPSIDRA), has been dosed in over 100 cancer patients, and benefits from collaborations such as a CRADA with the U.S. NCI and orphan designations for SCLC and AML. The company’s team is based in Barcelona, with presence in Boston and San Diego. The announced financing with Nice & Green is intended to strengthen the balance sheet and extend cash runway to support ongoing pivotal activities and partner discussions. Oryzon Genomics is a clinical-stage biopharmaceutical company founded in 2000 in Barcelona that develops therapies based on epigenetics for oncology and neurodegenerative diseases. Its lead programs are ORY-1001 for acute myeloid leukemia and ORY-2001 for cognitive decline and memory loss, with ORY-1001 entering Phase IIA enrollment and ORY-2001 expected to begin human trials in early 2016. Oryzon also advances earlier-stage epigenetic-targeted programs and operates a biomarker identification and validation platform; its LSD1 program is covered by 19 patent families. The company completed a $19 million private placement that issued 4.9 million new common shares at €3.39 per share and values the company at $110 million post-transaction. Proceeds will be used to advance ORY-1001 and ORY-2001 and to accelerate earlier-stage programs, complementing potential milestone payments from Roche tied to a strategic collaboration for ORY-1001 with possible value above $500 million. Oryzon opened U.S. operations in Cambridge, Massachusetts in 2014 and expects to list on the Madrid Stock Exchange before year-end with a potential future dual listing on NASDAQ.